Litcius/Paper detail

Identification and structural studies of natural inhibitors against SARS-CoV-2 viral RNA methyltransferase (NSP16)

Mukesh Kumar, Anik Roy, Ravindra Singh Rawat, Amit Alok, Kishore K. R. Tetala, Nihar Ranjan Biswas, Punit Kaur, Sanjit Kumar

2021Journal of Biomolecular Structure and Dynamics18 citationsDOI

Abstract

virtual screening, docking and Molecular Dynamics (MD) simulation studies were performed to understand how these potential inhibitors are bound to NSP16. We observed that the most highly screened compound binds to protein molecules with a high dock score, primarily through hydrophobic interactions and hydrogen bonding, as previously reported for NSP16. Compound-13 (2-hydroxy-N-({1-[2-hydroxy-1-(hydroxymethyl)ethyl]piperidin-3-yl}methyl)-5-methylbenzamide) and compound-51 (N-(2-isobutoxybenzyl)-N,2-dimethyl-2,8-diazaspiro[4.5]decane-3-carboxamide) occupied in active site along with good pharmokinetices properties. In conclusion, the selected compounds could be used as a novel therapeutic against SARS-CoV-2.Communicated by Ramaswamy H. Sarma.

Topics & Concepts

Identification (biology)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)BiologyMedicineEcologyInfectious disease (medical specialty)PathologyDiseaseComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 ResearchTuberculosis Research and Epidemiology
Identification and structural studies of natural inhibitors against SARS-CoV-2 viral RNA methyltransferase (NSP16) | Litcius